Security
ENvue Medical, Inc. Common Stock · FEED
FEEDOTCCommon stockCurrentCIK 1326706Updated Oct 15, 2026
Name history
NanoVibronix, Inc. · through Dec 12, 2025Nano Vibronix, Inc. · through Mar 25, 2014Nano Vibronix Inc · through May 5, 2005
FEED price & chart
Loading TradingView…
OTC:FEED on TradingView ↗About the company
NanoVibronix, Inc. (NASDAQ: NAOV) is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Nesher, Israel, the Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield® and UroShield®, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
In the news
No coverage from other publishers is available.
Recent filings
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 1.01, 2.03, 5.03, 9.01
EFFECT filing
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Other Events
Items 5.03, 8.01, 9.01
10-Q filing
NT 10-Q filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 54,383,000Source | 4,682,000Source | 38,405,000Source | 51,482,000Source | 5,696,000Source | 39,871,000Source | 44,105,000Source | 6,235,000Source | 41,124,000Source | 3,629,000Source | 6,674,000Source | 5,879,000Source |
| Property, Plant and Equipment, NetUSD | 124,000Source | 9,000Source | 145,000Source | 112,000Source | 9,000Source | 127,000Source | 125,000Source | 8,000Source | 119,000Source | 9,000Source | 7,000Source | 7,000Source |
| GoodwillUSD | 38,631,000Source | — | 29,082,000Source | 38,631,000Source | — | 29,082,000Source | 33,909,000Source | — | 29,082,000Source | — | — | — |
| Intangible Assets, Net (Excluding Goodwill)USD | 5,275,000Source | — | 3,962,000Source | 5,516,000Source | — | 4,172,000Source | 5,880,000Source | — | 4,380,000Source | — | — | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 6,950,000Source | 1,305,000Source | 1,084,000Source | 4,030,000Source | — | 2,235,000Source | 571,000Source | — | 4,224,000Source | — | — | — |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 252,000Source | 580,000Source | 205,000Source | 115,000Source | 489,000Source | 332,000Source | 358,000Source | 360,000Source | 289,000Source | 98,000Source | 318,000Source | 9,000Source |
| Inventory, NetUSD | 2,243,000Source | 2,250,000Source | 2,581,000Source | 2,206,000Source | 2,431,000Source | 2,266,000Source | 2,019,000Source | 2,588,000Source | 2,337,000Source | 2,191,000Source | 2,732,000Source | 2,175,000Source |
| Assets, CurrentUSD | 10,015,000Source | 4,377,000Source | 4,818,000Source | 6,892,000Source | 5,386,000Source | 6,197,000Source | 3,859,000Source | 5,945,000Source | 7,271,000Source | 3,331,000Source | 6,487,000Source | 5,609,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 540,000Source | 242,000Source | — | 511,000Source | 296,000Source | — | 881,000Source | 297,000Source | — | 290,000Source | 154,000Source | 712,000Source |
| Operating Lease, Right-of-Use AssetUSD | 125,000Source | 126,000Source | 243,000Source | 145,000Source | 133,000Source | 148,000Source | 161,000Source | 110,000Source | 127,000Source | 116,000Source | 5,000Source | 81,000Source |
| Other Assets, NoncurrentUSD | — | — | — | — | 1,000Source | — | — | 1,000Source | — | — | 1,000Source | 3,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 11,919,000Source | 2,810,000Source | 7,647,000Source | 11,005,000Source | 2,855,000Source | 7,856,000Source | 8,430,000Source | 2,731,000Source | 7,627,000Source | 3,002,000Source | 2,686,000Source | 2,646,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 1,000Source | 3,000Source | 8,000Source | 8,000Source | 2,000Source | 4,000Source | 1,000Source | 2,000Source | 1,000Source | 3,000Source | 2,000Source | 2,000Source |
| Additional Paid in CapitalUSD | 119,408,000Source | 70,314,000Source | 155,278,000Source | 116,542,000Source | 70,284,000Source | 144,227,000Source | 108,051,000Source | 70,256,000Source | 124,057,000Source | 70,505,000Source | 70,149,000Source | 65,634,000Source |
| Retained Earnings (Accumulated Deficit)USD | -76,858,000Source | -68,370,000Source | -124,448,000Source | -75,988,000Source | -67,372,000Source | -112,136,000Source | -72,296,000Source | -66,684,000Source | -90,481,000Source | -69,801,000Source | -66,096,000Source | -62,385,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -87,000Source | -75,000Source | -80,000Source | -85,000Source | -73,000Source | -80,000Source | -81,000Source | -70,000Source | -80,000Source | -80,000Source | -67,000Source | -18,000Source |
| Stockholders' Equity Attributable to ParentUSD | 42,464,000Source | 1,872,000Source | 30,758,000Source | 40,477,000Source | 2,841,000Source | 32,015,000Source | 35,675,000Source | 3,504,000Source | 33,497,000Source | 627,000Source | 3,988,000Source | 3,233,000Source |
| Liabilities and EquityUSD | 54,383,000Source | 4,682,000Source | 38,405,000Source | 51,482,000Source | 5,696,000Source | 39,871,000Source | 44,105,000Source | 6,235,000Source | 41,124,000Source | 3,629,000Source | 6,674,000Source | 5,879,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 11,644,000Source | 2,521,000Source | 7,305,000Source | 6,543,000Source | 2,556,000Source | 6,865,000Source | 8,200,000Source | 2,427,000Source | 6,660,000Source | 2,722,000Source | 2,454,000Source | 2,316,000Source |
| Operating Lease, Liability, CurrentUSD | 112,000Source | 49,000Source | 162,000Source | 81,000Source | 44,000Source | 95,000Source | 148,000Source | 24,000Source | 89,000Source | 52,000Source | 5,000Source | 81,000Source |
| Accounts Payable, CurrentUSD | 492,000Source | 25,000Source | 839,000Source | 270,000Source | 92,000Source | 706,000Source | 149,000Source | 37,000Source | 719,000Source | 47,000Source | 138,000Source | 66,000Source |
| Operating Lease, Liability, NoncurrentUSD | 15,000Source | 77,000Source | 68,000Source | 69,000Source | 89,000Source | 35,000Source | 17,000Source | 86,000Source | 28,000Source | 64,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Accounts Receivable, after Allowance for Credit LossUSD | — | 580,000Source | — | — | — | — | 358,000Source | — | — | 98,000Source | — | — |
| Long-term Debt | — | — | — | — | — | — | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 217,000Source | 18,000Source | 897,000Source | 1,000Source | 1,000Source | 1,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | — | — | — | 356,000Source | 293,000Source | 354,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 43,000Source | 228,000Source | 179,000Source | -221,000Source | 309,000Source | -191,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -71,000Source | -567,000Source | -249,000Source | -541,000Source | 557,000Source | 2,000,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -373,000Source | -830,015Source | -1,267,000,000Source | -893,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -4,312,000Source | -1,343,000Source | -9,372,000Source | -2,516,000Source | -3,602,000Source | -7,035,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -17,000Source | 143,000Source | 88,000Source | -3,000Source | -1,000Source | -3,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 17,000Source | 5,000Source | 60,000Source | 3,000Source | 1,000Source | 3,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 2,340,000Source | 1,050,000Source | 12,786,000Source | 1,000Source | 4,222,000Source | 2,092,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | — | — | — | — | — | — | 12,000Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -1,989,000Source | -151,000Source | 3,502,000Source | -2,531,000Source | 570,000Source | -5,024,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 6,980,000Source | 1,305,000Source | 1,141,000Source | 4,060,000Source | 2,265,000Source | 601,000Source | 4,254,000Source | 752,000Source | — | — |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 25,000Source | — | — | — |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 1,000Source | — | 52,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | — | — | — | — | — | — | 356,000,000Source | 292,000,000Source | 354,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 210,000Source | 17,000Source | 855,000Source | — | — | — |
| Equity Securities, FV-NI, Gain (Loss)USD | — | — | — | — | — | — | — | 58,000Source | — | — | -2,000Source | -16,000Source |
| Gain (Loss) on Sale of InvestmentsUSD | — | — | — | — | — | — | — | — | — | -1,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 1,403,000Source | 673,000Source | 3,500,000Source | 2,252,000Source | 2,416,000Source | 1,342,000Source | 7,633,000Source | 3,461,000Source | 3,924,000Source | 3,931,000Source |
| GoodwillUSD | — | — | 38,631,000Source | — | 29,082,000Source | 38,631,000Source | 29,082,000Source | 33,909,000Source | 29,082,000Source | — | — | — |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | 0Source | 0Source | 10,509,000Source | — | — | — |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | 645,000Source | — | — | — |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | -645,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | 35,000Source | 3,000Source | -2,000Source | 62,000Source | 33,000Source | 15,000Source | -307,000Source | 19,000Source | 29,000Source | 35,000Source |
| Inventory Write-downUSD | — | — | — | — | — | — | 122,000Source | 0Source | 346,000Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | 510,000Source | -998,000Source | -4,899,000Source | -3,971,000Source | -3,822,000Source | -1,872,000Source | -18,185,000Source | -3,705,000Source | -3,711,000Source | -5,448,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -780,000Source | -998,000Source | -12,164,000Source | -500,000Source | -22,621,000Source | -1,872,000Source | -16,775,000Source | -3,705,000Source | -3,711,000Source | -5,448,000Source |
| Operating ExpensesUSD | — | — | 2,436,000Source | 1,103,000Source | 5,208,000Source | 3,941,000Source | 3,656,000Source | 2,221,000Source | 23,042,000Source | 5,090,000Source | 4,973,000Source | 5,179,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | 70,000Source | — | 70,000Source | 70,000Source | 75,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 4,215,000Source | 2,090,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | — | 1,300,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | 102,000Source | — | 7,000Source | 2,000Source |
| InterestExpenseNonoperating | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 722,000Source | 376,000Source | 239,000Source | 494,000Source | 653,000Source | 1,025,000Source | 2,553,000Source | 2,558,000Source | 2,283,000Source | 752,000Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Operating Income (Loss)USD | — | — | -2,247,000Source | -970,000Source | -5,474,000Source | -3,976,000Source | -3,711,000Source | -1,852,000Source | -22,889,000Source | -3,582,000Source | -3,436,000Source | -5,012,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 545,000Source | -995,000Source | -4,901,000Source | -3,909,000Source | -3,789,000Source | -1,857,000Source | -18,492,000Source | -3,686,000Source | -3,682,000Source | -5,413,000Source |
| Income Tax Expense (Benefit)USD | — | — | 35,000Source | 3,000Source | -2,000Source | 62,000Source | 33,000Source | 15,000Source | -307,000Source | 19,000Source | 29,000Source | 35,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 510,000Source | -998,000Source | -4,899,000Source | -3,971,000Source | -3,822,000Source | -1,872,000Source | -18,185,000Source | -3,705,000Source | -3,711,000Source | -5,448,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.91Source | -3.56Source | -1.98Source | -1.03Source | -6.88Source | -29.9Source | -26.69Source | -13.73Source | -2.12Source | -3.84Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.91Source | -3.56Source | -1.98Source | -1.03Source | -6.88Source | -29.9Source | -26.69Source | -13.73Source | -2.12Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 858,434Source | 280,318Source | 6,157,249Source | 484,566Source | 3,289,049Source | 62,615Source | 628,534Source | 269,848Source | 1,750,109Source | 1,419,670Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 858,434Source | 280,318Source | 6,157,249Source | 484,566Source | 3,289,049Source | 62,615Source | 628,534Source | 269,848Source | 1,750,109Source | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 210,000Source | 17,000Source | 855,000Source | — | — | — |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 66,000Source | 18,677Source | -25,000,000Source | 37,000Source |
| General and Administrative ExpenseUSD | — | — | 1,403,000Source | 673,000Source | 3,500,000Source | 2,252,000Source | 2,416,000Source | 1,342,000Source | 7,633,000Source | 3,461,000Source | 3,924,000Source | 3,931,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | 0Source | 0Source | 10,509,000Source | — | — | — |
| Gross ProfitUSD | — | — | 189,000Source | 133,000Source | -266,000Source | -35,000Source | -55,000Source | 369,000Source | 153,000Source | 1,508,000Source | 1,537,000Source | 167,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 18,713,000Source | 3,775,000Source | 3,785,000,000Source | 5,557,000Source |
| Interest ExpenseUSD | — | — | — | 33,000Source | — | 144,000Source | — | 53,000Source | — | 135,000Source | 135,000Source | 347,000Source |
| Marketing and Advertising ExpenseUSD | — | — | — | 11,000Source | — | — | — | 8,000Source | — | 53,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -780,000Source | -998,000Source | -12,164,000Source | -500,000Source | -22,621,000Source | -1,872,000Source | -16,775,000Source | -3,705,000Source | -3,711,000Source | -5,448,000Source |
| Operating ExpensesUSD | — | — | 2,436,000Source | 1,103,000Source | 5,208,000Source | 3,941,000Source | 3,656,000Source | 2,221,000Source | 23,042,000Source | 5,090,000Source | 4,973,000Source | 5,179,000Source |
| Operating Lease, ExpenseUSD | — | — | — | — | — | — | — | 70,000Source | — | 70,000Source | 70,000Source | 75,000Source |
| Preferred Stock Dividends and Other AdjustmentsUSD | — | — | — | — | — | -3,815,000Source | — | — | 399,000Source | — | — | — |
| Research and Development ExpenseUSD | — | — | 221,000Source | 249,000Source | 510,000Source | 1,016,000Source | 468,000Source | 530,000Source | 1,762,000Source | 909,000Source | 185,000Source | 283,000Source |
| Selling and Marketing ExpenseUSD | — | — | 812,000Source | 181,000Source | 1,198,000Source | 673,000Source | 772,000Source | 349,000Source | 2,493,000Source | 720,000Source | 864,000Source | 965,000Source |
| Interest Expense (non-operating) | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
Offerings
Registration 333-298188
Registration 333-296001
Registration 333-284973
- Gross proceeds
- 10000000.0
- Net proceeds
- 9300000.0
- Deal price
- 25.0
- Shares
- 400000
- Offering price
- $25
- Ticker
- NAOV
Filing attachments
ex99-1.htm · 8-K · 2026-08-31
Exhibit 99.1 ENvue Medical, Inc. Announces 1-for-12 Reverse Stock Split TYLER, Texas, August 28, 2026 (GLOBE NEWSWIRE) - ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical technology company, today announced that a reverse stock split of the Company’s issued and outstanding common stock, par value $0.001 per share (the “Common Stock”) at a ratio of 1-for-12 is expected to become effective on September 1, 2026. The Company’s Common Stock will begin trading…
Read attachment ↗ex107.htm · S-3 · 2026-08-10
Calculation of Filing Fee Tables S-3 ENvue Medical, Inc. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggr…
Read attachment ↗ex107.htm · S-3 · 2026-05-18
Calculation of Filing Fee Tables S-3 ENvue Medical, Inc. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering P…
Read attachment ↗ex4-16.htm · 10-K · 2026-04-15
Exhibit 4.16 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 31, 2026, ENvue Medical, Inc., a Delaware corporation (formerly NanoVibronix, Inc.) (“we,” “our” and the “Company”) has its common stock, par value $0.001 per share, registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following description is intended as a summary and is qualified in its entirety by reference to our Amended and Restated C…
Read attachment ↗ex99-1.htm · 8-K · 2025-12-12
EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 NanoVibronix, Inc. Announces Name and Ticker Symbol Change to ENvue Medical, Inc. and ‘FEED’ New ticker symbol, “FEED” will begin trading on the Nasdaq at the open of the market on December 12, 2025 TYLER, Texas December 12, 2025 - ( BUSINESS WIRE ) - NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company specializing in non-invasive therapeutic systems, today announced that it will change its corporate n…
Read attachment ↗ex99-1.htm · 8-K · 2025-11-19
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 NanoVibronix Issues Letter to Shareholders ENvue® Feeding Tube Placement System Identified as Core Growth Platform Strategic Rebranding and Name Change to Reflect Company’s Focus on Multi-Billion-Dollar Enteral-Feeding Market The Company is Considering Strategic Alternatives for Legacy Assets TYLER, Texas, November 19, 2025 - ( BUSINESS WIRE ) - NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or the “Company”), a medical technology company spe…
Read attachment ↗